What is Olivier Harismendy email address?

Olivier Harismendy's primary email address is ******************@free.fr. To view the full verified email and additional contact details, sign up for free with Muraena.

What company does Olivier Harismendy work for?

Olivier Harismendy is a Vice President, Translational Data Science and Computational Biology at Zentalis Pharmaceuticals, a company specializing in Commercial physical research.

Where Olivier Harismendy graduated from?

Olivier Harismendy holds a degree in Biology from Loyola University Maryland.

How can I directly contact Olivier Harismendy?

To contact Olivier Harismendy directly, you can use the email address ******************@free.fr. Complete contact information is available upon registration with Muraena.

Is Olivier Harismendy an immigrant?

Yes, Olivier Harismendy is an immigrant and currently based in United States

Who is Olivier Harismendy?

Olivier Harismendy is a seasoned professional with over 22 years of experience in generating and analyzing large genomic datasets, specializing in translational cancer research for the past 14 years. Currently serving as Vice President of Translational Data Science at Zentalis Pharmaceuticals, Olivier leads innovative data-driven approaches for cancer biomarker discovery, integrating expertise from molecular biology, process engineering, and biomedical data science. His academic background includes significant roles at UC San Diego, where he contributed to both teaching and research in genomics and informatics. Olivier's work has been recognized through numerous publications in prestigious journals, highlighting his contributions to the field. With a strong foundation in bioinformatics and computational biology, he is well-versed in leveraging machine learning techniques to advance cancer research. His leadership experience spans both academic and corporate environments, making him a versatile figure in scientific research and development. Passionate about the intersection of technology and life sciences, Olivier continues to drive impactful research initiatives.